Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes GuidanceInvestors Business Daily • 10/27/20
Week 44 MDA Breakout Forecast - October: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/25/20
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination EffortsBusiness Wire • 10/22/20
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020Business Wire • 10/21/20
Merck (MRK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/20/20
Merck Posts Positive Data For Pneumococcal Vaccine Candidate, Eyes ApprovalInvestors Business Daily • 10/20/20
Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate VaccineBusiness Wire • 10/20/20
Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung CancerBusiness Wire • 10/16/20
Merck KGaA, Darmstadt, Germany, Announces Retirement of Luciano Rossetti, Global Head of R&D for HealthcarePRNewsWire • 10/15/20